CDC20 and breast carcinoma: To characterize the effect of Cdc20 PROTACs, we have systematically measured the dose-dependent Cdc20 degradation stimulated by each of the 15 designed Cdc20 PROTACs in various breast cancer cells, including MCF7 and MDA-MB-231 cells.